Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known. METHODS: We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition. Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks. The primary end point was the percentage change in body weight from baseline to 24 weeks. Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more. Safety was also assessed. RESULTS: We enrolled 338 adults, 51.8% of whom were men. The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was -7.2% in the 1-mg group, -12.9% in the combined 4-mg group, -17.3% in the combined 8-mg group, and -17.5% in the 12-mg group, as compared with -1.6% in the placebo group. At 48 weeks, the least-squares mean percentage change in the retatrutide groups was -8.7% in the 1-mg group, -17.1% in the combined 4-mg group, -22.8% in the combined 8-mg group, and -24.2% in the 12-mg group, as compared with -2.1% in the placebo group. At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of those who received placebo. The most common adverse events in the retatrutide groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg). Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter. CONCLUSIONS: In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT04881760.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D.”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [45]
Experimental — accuracy not yet measuredIn the citing paper
“e24.2 (95% CI, e26.6 to e21.8) in the 12 mg with an ID of 2 mg group as compared with e2.1 (95% CI, e3.5 to e0.7) in the placebo group.”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Jastreboff et al, 2023
In the citing paper
“Retatrutide 1-12 mg/week over 48 weeks (primary endpoint for bodyweight: 24 weeks) Up to 22•1% (19•3-24•9) with 12 mg/week Up to 0•5% (0•3-0•6) with 8 mg (initial dose 2 mg)/week High drug discontinuation due to adverse events (up to 16% with 12 mg/week); discontinuation for any reason up to 23•5% (with 4 mg/week); weight plateau not reached Jastreboff et al (2023) 138”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [138]
In the citing paper
“In the retatrutide phase 2 trial for people with overweight or obesity (BMI ≥30 kg/m²), or with a BMI of at least 27 kg/m² with one or more weight-related condition, the mean bodyweight reduction at week 48 in the retatrutide (12 mg once-weekly) groups was up to 24•2% (95% CI 21•8-28•6) compared with 2•1% (0•7-3•5) with placebo.138”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [138]
In the citing paper
“However, these resulted in not-so-rare incidents of therapy discontinuation, and their intensity was clearly linked with higher dosages.”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [39]
114 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Physical Activity Guidelines for Americans
Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., George, S. M., & Olson, R. D. (2018) · JAMA · doi:10.1001/jama.2018.14854 · Cited by 9,755
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Self-citationA rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Aminian, A., Al-Kurd, A., Wilson, R., Bena, J., Fayazzadeh, H., Singh, T., Albaugh, V. L., Shariff, F. U., Rodriguez, N. A., Jin, J., et al. (2021) · JAMA · doi:10.1001/jama.2021.19569 · Cited by 375
Cited by
Items 201–300 of 1,139
Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
Zhou, D., & Fan, J. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003355 · Cited by 30
Zhou, X., Fan, Q.-Y., Byrne, C. D., Targher, G., Muthiah, M. D., Huang, D. Q., Chen, Q., Noureddin, M., Li, W., Ratziu, V., et al. (2025) · Gut · doi:10.1136/gutjnl-2025-337431 · Cited by 44
“40 Notably, in the retatrutide-related trial, heart rate peaked around 6 months and then declined, suggesting these drugs may be better suited for generally healthy individuals and warrant cardiovascular monitoring.”
Gastrointestinal Motility Effects of GLP-1 Receptor Agonists
Bellavance, D. R., Chua, S. G., & Mashimo, H. L. (2025) · Current Gastroenterology Reports · doi:10.1007/s11894-025-00995-3 · Cited by 33
“A combination GLP-1/GIP/glucagon RA, or so called “triple agonist”, has recently demonstrated ability to promote profound weight loss in a recent phase 2 RCT [93].”
Dash, S. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15829 · Cited by 24
“72 A potential advantage of glucagon receptor agonism is that it may attenuate the decline in energy expenditure seen with weight loss, but this awaits confirmation.”
InfluentialRecent advances in peptide-based therapies for obesity and type 2 diabetes
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2024) · Peptides · doi:10.1016/j.peptides.2024.171149 · Cited by 25
“Of particular note, the synthetic triple GLP-1R/GIPR/ GCGR agonist peptide retatrutide (12 mg once weekly by subcutaneous injection) achieved a weight reduction of 24% during a 48 week study in overweight and obese individuals [35].”
BackgroundCastañé, H., Jiménez-Franco, A., Hernández‐Aguilera, A., Martínez-Navidad, C., Cambra-Cortés, V., Onoiu, A.-I., Jiménez-Aguilar, J. M., París, M., Hernández, M., Parada, D., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105532 · Cited by 34
Torbahn, G., Lischka, J., Brown, T. J., Ells, L. J., Kelly, A. S., Wabitsch, M., & Weghuber, D. (2024) · Clinical Endocrinology · doi:10.1111/cen.15133 · Cited by 33
GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
Cooper, M. E., & van Raalte, D. H. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194749 · Cited by 24
“Preliminary data point toward beneficial effects of GIP agonism, as reported in findings from the SURPASS program that tirzepatide reduced UACR and slowed down eGFR declined in comparison with both placebo (53) and comparator drugs including insulin glargine (74, 75).”
InfluentialSemaglutide for weight loss: unanswered questions
Tzoulis, P., & Baldeweg, S. E. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1382814 · Cited by 30
“…fi t more from alternative pharmacotherapies, such as dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist (30) or combination of GLP-1 agonist an amylin analogue (31) or triple GLP-1, GIP and glucagon receptors agonist (32), or endoscopic procedures or bariatric surgery (27).”
BackgroundFan, W., Bradford, T. M., & Török, N. J. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15184 · Cited by 25
The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue
Kagdi, S., Lyons, S. A., & Beaudry, J. L. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0361 · Cited by 33
The (dys)regulation of energy storage in obesity
Levin, B. E., Geary, N., & Lutz, T. A. (2025) · Physiological Reviews · doi:10.1152/physrev.00002.2024 · Cited by 29
Anastasiou, I. A., Argyrakopoulou, G., Dalamaga, Μ., & Kokkinos, A. D. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00623-1 · Cited by 29
Review of current and new drugs for the treatment of metabolic-associated fatty liver disease
Gish, R. G., Fan, J., Dossaji, Z., Fichez, J., Laeeq, T., Chun, M. J., & Boursier, J. (2024) · Hepatology International · doi:10.1007/s12072-024-10698-y · Cited by 26
The GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicines
Douros, J. D., Mokrosiński, J., & Finan, B. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0226 · Cited by 31
Glucose-dependent insulinotropic polypeptide receptor signaling alleviates gut inflammation in mice
Hammoud, R., Kaur, K. D., Koehler, J. A., Baggio, L. L., Wong, C. K., Advani, K. E., Yusta, B., Efimova, I., Gribble, F. M., Reimann, F., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.174825 · Cited by 24
“…coagonists such as TZP are now approved for T2D and obesity, retatrutide — the GIPR-biased triple agonist— is in phase 3 clinical trials (41) and the GIPR antagonist-GLP-1RA, AMG-133, is also being studied in phase 2/3 trials (2, 4); therefore, understanding how gain and loss of GIPR…”
Leslie, J., Krishnamurthy, K. A., Gopalsamy, I. K., Inácio, P., Huch, M., Gallage, S., Oakley, F., & Vacca, M. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01162-9 · Cited by 30
Rubio, M. Á., Carreiro, S. M., Sánchez-Pernaute, A., & Ramos-Levi, A. M. (2023) · Biomedicines · doi:10.3390/biomedicines11102785 · Cited by 28
Skeletal muscle loss and sarcopenia in obesity pharmacotherapy
Hope, D. C. D., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01041-4 · Cited by 29
“This proportion of LBM to total body-weight loss observed is consistent with semaglutide 1.0 mg once weekly in the SUSTAIN 8 trial 4 .”
InfluentialEvolving Approaches for Pharmacological Therapy of Obesity
Chao, A. M., Taylor, S. I., Moore, M., Amaro, A., & Wadden, T. A. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-031124-101146 · Cited by 30
Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy
Nicze, M., Dec, A., Borówka, M., Krzyżak, D., Bołdys, A., Bułdak, Ł., & Okopień, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158202 · Cited by 33
Heckmann, N. D., Palmer, R. C., Mayfield, C. K., Gucev, G., Lieberman, J. R., & Hong, K. M. (2024) · Arthroplasty Today · doi:10.1016/j.artd.2024.101327 · Cited by 22
Role of the Intestine and Its Gut Microbiota in Metabolic Syndrome and Obesity
Busch, C. B. E., Bergman, J. J. G. H. M., Nieuwdorp, M., & van Baar, A. C. G. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002730 · Cited by 27
Langer, H. T., Gilmore, N. K., Hayden, C. M. T., Roux, J., Bariohay, B., Rouquet, T., Awada, M., Marcotorchino, J., Bournot, L., Nunn, E., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102665 · Cited by 21
Triple–Hormone-Receptor Agonist Retatrutide for Obesity
(2023) · New England Journal of Medicine · doi:10.1056/nejmc2310645 · Cited by 21
Structured lifestyle modification as an adjunct to obesity pharmacotherapy: there is much to learn
Murphy, E. E., & Finucane, F. M. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01499-2 · Cited by 23
“Semaglutide [2], a glucagon-like peptide-1 receptor agonist (GLP-1RA), is the fi rst of these new agents to obtain regulatory approval for the treatment of obesity, with tirzepatide [3] and other drugs [4] showing even stronger potential.”
Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management
Alhomoud, I. S., Talasaz, A. H., Chandrasekaran, P., Brown, R., Mehta, A., & Dixon, D. L. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4607 · Cited by 28
“, 59, 60, 62, 63 obesity or overweight and Additionally, 83% of participants in the semaglutide 2.4 mg group and 72% in the semaglutide 1.7 mg group achieved a weight reduc - tion of ≥5% compared with 21% in the placebo group ( p 0.0001).”
InfluentialWeight Gain and Glycemic Control in Adults with Type 1 Diabetes in the T1D Exchange Registry
Bailey, R., Calhoun, P., & Garg, S. K. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0389 · Cited by 21
Jalil, J., Gabrielli, L., Ocaranza, M. P., MacNab, P., Fernández, R., Grassi, B. A., Jofré, P., Verdejo, H., Acevedo, M., Córdova, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084407 · Cited by 28
Role of MASLD in CVD: A review of emerging treatment options
Mollace, R., Longo, S., Nardin, M., Tavernese, A., Musolino, V., Cardamone, A., & Federici, M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111891 · Cited by 29
Gaggini, M., Sabatino, L., Suman, A. F., Chatzianagnostou, K., & Vassalle, C. (2025) · Cells · doi:10.3390/cells14050387 · Cited by 35
“In adults with obesity, LY3437943 treatment for 48 weeks induced significant body weight lowering; the most common adverse effects were gastrointestinal, dose-related, mild–moderate, and reduced in part by a lower starting dose (2 mg vs. 4 mg) [131].”
Triple Agonism Based Therapies for Obesity
Goldney, J., Hamza, M., Surti, F., Davies, M. J., & Papamargaritis, D. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00770-z · Cited by 22
“3) [8, 27, 45, 46, 49, 50].”
InfluentialGLP-1 physiology and pharmacology along the gut-brain axis
Beutler, L. R. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194744 · Cited by 35
“First, multiple-agonist therapies, including the FDA-approved GLP-1/GIP receptor coagonist tirzepatide, are more effective at promoting weight loss than GLP-1R monoagonists, including semaglutide (135–137).”
Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists
Jensen, E., Israelsen, M. E., & Krag, A. A. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000561 · Cited by 25
“[56,57] Thus, sustained weight loss is crucial for reducing liver-related morbidity and mortality in SLD.”
BackgroundHFpEF and MASLD: converging mechanisms and clinical implications
Capone, F., Häseli, S. P., Liu, L., Strocchi, S., Langenberg, C., Lusis, A. J., Pietzner, M., Muoio, D. M., Rider, O. J., Raman, B., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01257-z · Cited by 37
“…(including semaglutide) 365 , double GLP1–gastric inhibitory polypeptide receptor agonists (tirzepatide) 366 and triple GLP1– gastric inhibitory polypeptide receptor–glucagon receptor agonists (retatrutide) 367 , increase insulin secretion, suppress glucagon release and slow gastric emptying.”
Heerspink, H. J. L., Lu, Z., Du, Y., Duffin, K. L., Coskun, T., Haupt, A., & Hartman, M. L. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.03.049 · Cited by 23
“14,15 We report least-squares means with standard errors and least-squares mean differences with 95% CI, and P -values for treatment comparisons.”
InfluentialSelf-citationMuzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
Chetty, A. K., Rafi, E., Bellini, N. J., Buchholz, N., & Isaacs, D. M. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.12.010 · Cited by 23
A comprehensive review of genetic causes of obesity
Concepción‐Zavaleta, M. J., Aldave, J. E. Q., Durand‐Vásquez, M. D. C., Osorio, E. R. G., de la Cruz, J. D. C. V., Barrueto-Callirgos, C. M., Puelles‐León, S. L., Alvarado-León, E. D. J., Cabrera, F. A. L., Zavaleta‐Gutiérrez, F. E., et al. (2023) · World Journal of Pediatrics · doi:10.1007/s12519-023-00757-z · Cited by 28
“However, currently, there are no studies on their use in obesity caused by genetic factors [126, 137].”
Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease
Bołdys, A., Bułdak, Ł., Maligłówka, M., Surma, S., & Okopień, B. (2023) · Medicina · doi:10.3390/medicina59101789 · Cited by 25
“[60].”
Valdecantos, M. P., Ruiz, L., Folgueira, C., Rada, P., Gómez‐Santos, B., Solas, M., Hitos, A. B., Field, J., Francisco, V., Escalona-Garrido, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54080-w · Cited by 24
Sinha, B., & Ghosal, S. (2025) · Obesity · doi:10.1002/oby.24360 · Cited by 31
Saldívar-Cerón, H. I., Vargas-Camacho, J. A., León‐Cabrera, S., Briseño-Díaz, P., Castañeda-Ramírez, A. E., Muciño-Galicia, A. E., & Díaz-Domínguez, M. R. (2025) · Scientia Pharmaceutica · doi:10.3390/scipharm93020026 · Cited by 25
Finan, B., Douros, J. D., Goldwater, R., Hansen, A. M. K., Hjerpsted, J., Hjøllund, K. R., Kankam, M. K., Knerr, P. J., Konkar, A. A., Mowery, S. A., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102129 · Cited by 21
“It appears that tri-agonism therapy provides maximal ef fi cacy, which has been further validated by the emerging results with retatrutide [26].”
InfluentialBeyond Glucose—Rethinking Prediabetes for Precision Prevention
Wagner, R. J., Selvin, E., Sehgal, R., Prystupa, K., Misra, S., Fritsche, A., & Heni, M. (2025) · Diabetes Care · doi:10.2337/dci25-0054 · Cited by 30
Pharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease
Jaoudeh, R. A. R. A., Hartmann, P., Olson, O., Gupta, O. T., Kumar, S., Ibrahim, S. H., Fawaz, R. L., Aqul, A. A., & Hassan, S. M. (2024) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.12402 · Cited by 23
Gudzune, K. A., Kaplan, L. M., Kahan, S. I., Kumar, R. B., Dunn, J. P., Ahmad, N. N., Poon, J. L., Sims, T. J., Mackie, D. S., Jauregui, A. K., et al. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.06.009 · Cited by 22
Self-citationThe role of incretin receptor agonists in the treatment of obesity
Forst, T. M., Block, C. E. M. D., Prato, S. D., Armani, S., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15796 · Cited by 22
“128 Long-term safety data for the newer incretin-based therapies for obesity are needed.”
Self-citationPharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists
Myerson, M. L., & Paparodis, R. D. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2487 · Cited by 20
“47 Orforglipron, being developed by Eli Lilly, is a novel small molecule (LY3502970: molecular weight: 882.96, formula: C 48 H 48 F 2 N 10 O 5 ) oral non-peptide GLP-1 receptor agonist, which acts by potently activating the G-protein coupled receptor of the GLP-1 differently than that activated by…”
InfluentialGLP-1 Receptor Agonists – Good for Body Weight, Bad for Micronutrient Status?
Kerlikowsky, F., Krämer, K., Eggersdorfer, M., & Hahn, A. (2025) · Current Developments in Nutrition · doi:10.1016/j.cdnut.2025.107587 · Cited by 18
“However, compelling empirical observations offer an effective approach as an AOM to counteract the global rise in obesity prevalence [9,10].”
Nutritional Mechanisms of Cancer Cachexia
Compton, S. L. E., Heymsfield, S. B., & Brown, J. C. (2024) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-062122-015646 · Cited by 26
Glucagon-Like Peptide-1 Agonists: A Practical Overview for Plastic and Reconstructive Surgeons
Stanton, E. W., Manasyan, A., Banerjee, R., Hong, K. M., Koesters, E. C., & Daar, D. A. (2024) · Annals of Plastic Surgery · doi:10.1097/sap.0000000000004089 · Cited by 23
Weight Loss Treatment and Longitudinal Weight Change Among Primary Care Patients With Obesity
Henderson, J., Ehlers, A. P., Lee, J. M., Kraftson, A. T., Piehl, K., Richardson, C. R., & Hafez, D. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.56183 · Cited by 21
Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective
Sidik, S. (2023) · Nature · doi:10.1038/d41586-023-02092-9 · Cited by 18
Gut microbiome and obesity care: Bridging dietary, surgical, and pharmacological interventions
Masi, D., Watanabe, M., & Clément, K. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102573 · Cited by 25
Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases
Himmerich, H., Bentley, J., & McElroy, S. L. (2024) · CNS Drugs · doi:10.1007/s40263-024-01111-1 · Cited by 29
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Sidrak, W. R., Kalra, S., & Kalhan, A. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_442_23 · Cited by 27
“[81] Results of phase II were presented in ADA 2023.”
Metabolic alliance: pharmacotherapy and exercise management of obesity
Butragueño, J., & Ruiz, J. R. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01006-7 · Cited by 18
“3 .”
Wulff, B. S., Chambers, A. P., Contreras, C. K. O., Kirkeby, K., Rinnov, A. R., Sustarsic, R. K., Østergaard, S., Laabs, J. E., & O'Neil, P. M. (2025) · Obesity · doi:10.1002/oby.24329 · Cited by 19
Phentermine in the Modern Era of Obesity Pharmacotherapy: Does It Still Have a Role in Treatment?
Lewis, K. H., Gudzune, K. A., & Ard, J. D. (2024) · Current Obesity Reports · doi:10.1007/s13679-023-00546-9 · Cited by 25
“With new triple-agonists like retatrutide reporting an average of 24% weight loss in Phase II clinical trials [64], phentermine is unlikely to achieve similar total percent weight loss, but it might be a cost-effective first-line option for patients with less severe obesity.”
Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity
Karam, L. B., Mabilleau, G., & Paccou, J. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07664-1 · Cited by 30
Dozens of new obesity drugs are coming: these are the ones to watch
Dolgin, E. (2025) · Nature · doi:10.1038/d41586-025-00404-9 · Cited by 19
Medicinal Polypharmacology in the Clinic – Translating the Polypharmacolome into Therapeutic Benefit
Rafehi, M., Möller, M., Al-khalil, W. I., & Stefan, S. M. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03656-8 · Cited by 23
Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.)
Moyad, M. A. (2023) · Current Urology Reports · doi:10.1007/s11934-023-01180-7 · Cited by 21
Liu, S., Hu, J., Zhao, C., Liu, H., & He, C. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1513641 · Cited by 17
Recent achievements and future directions of anti-obesity medications
Grandl, G., Novikoff, A., Liu, X., & Müller, T. D. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101100 · Cited by 32
Recent progress in the pharmacotherapy for obesity
Lu, J., Liu, P., Cai, M., Lv, T., Zhang, M., Yin, K., Cheng, J., & Zhang, G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177850 · Cited by 17
De Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Zhou, Q., Li, G., Hang, K., Li, J., Yang, D., & Wang, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061324-011832 · Cited by 16
Retatrutide showing promise in obesity (and type 2 diabetes)
Doggrell, S. A. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2283020 · Cited by 16
Reed, J., Bain, S. C., & Kanamarlapudi, V. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s415934 · Cited by 24
“314,315 Given GIP’s ability to promote glucagon secretion, it has been considered inappropriate to use clinically to treat T2D as it would amplify the hyperglycaemia associated with this disease.”
Jeyakumar, Y., Richardson, L., Sarma, S., Retnakaran, R. R., & Kramer, C. K. (2024) · BMJ Global Health · doi:10.1136/bmjgh-2024-017177 · Cited by 21
“10 Similarly, in the post hoc analyses of the semaglutide trial STEP-1, the estimated treatment difference in weight reduction in the semaglutide group compared with the group receiving placebo was −14.0% in women vs −8.0% in men.”
InfluentialSpezani, R., & Mandarim‐de‐Lacerda, C. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70400 · Cited by 25
“121,122 These distinctions form the basis for the qualitative evidence levels assigned in Table 2.”
Proglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 22
Xie, C., Alkhouri, N., & Elfeki, M. A. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i5.731 · Cited by 23
Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom
Knezović, E., Hefer, M., Blažanović, S., Petrović, A., Tomičić, V., Srb, N., Kirner, D., Smolić, R., & Smolić, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47030154 · Cited by 19
“Gastrointestinal adverse events were the most common and dose related, along with an increase in the heart rate at 24 weeks, but were generally mild to moderate [72].”
Obesity drug shortages are symptomatic of wider malaise
Sumithran, P., Finucane, F. M., & Cohen, R. V. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01963-3 · Cited by 16
Glenny, E. M., Coleman, M. F., Clutton, G. T., Riesenberg, B. P., Ho, A. N., McFarlane, T. L., Kiesel, V. A., Kucinskas, A. L., Bailey, E. G., Sanchez, K. E., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.20.576484 · Cited by 18
“While tirzepatide and retatrutide, a related GLP-1/GIP/glucagon receptor triple agonist, induce weight loss comparable to bariatric surgery 7,16,17 , their anticancer benefits are unknown.”
BackgroundSallam, M., Snygg, J., Ghandour, S. E., & Sallam, M. (2025) · Obesities · doi:10.3390/obesities5020026 · Cited by 21
Next-generation therapeutics for diabetic kidney disease
Yi, T. W., Sridhar, V. S., Scott, J., Nardone, M., & Cherney, D. Z. I. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01042-0 · Cited by 26
Dutta, D., Nagendra, L., Harish, B., Sharma, M., Joshi, A. S., Hathur, B., & Kamrul-Hasan, A. B. M. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_45_24 · Cited by 23
“[26] Again, gastrointestinal adverse events were the most common issues noted, which were found to be dose‑dependent and primarily seen at higher doses used for weight loss.”
Effect of GLP-1 receptor agonists on body composition
Bhandarkar, A. P., Bhat, S., & Kapoor, N. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000934 · Cited by 29
Spreckley, M., Ruggiero, C. F., & Brown, A. (2026) · Obesity Reviews · doi:10.1111/obr.70079 · Cited by 16
Contemporary Clinical Perspectives on Targeting Remission of Type 2 Diabetes
Retnakaran, R. R., Kashyap, S. R., Gerstein, H. C., & Aroda, V. R. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad746 · Cited by 19
Advances in incretin-based therapeutics for obesity
ROSENKILDE, M. M. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00938-w · Cited by 17
“In a phase II study including 338 adults, this compound resulted in weight loss of up to 25% in individuals with obesity 3 .”
Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges
Huang, X., Liu, J., Peng, G., Lu, M., Zhou, Z., Jiang, N., & Yan, Z. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0404 · Cited by 20
Kaur, M., & Misra, S. (2024) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2024-0065 · Cited by 18
Mechanisms and treatment of obesity-related hypertension—Part 2: Treatments
Parvanova, A. I., Abbate, M., Reseghetti, E., & Ruggenenti, P. L. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf035 · Cited by 23
Sarzani, R., Landolfo, M., Pentima, C. D., Ortensi, B., Falcioni, P., Sabbatini, L., Massacesi, A., Rampino, I., Spannella, F., & Giulietti, F. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1365183 · Cited by 26
Severe Insulin Resistance Syndromes: Clinical Spectrum and Management
Pliszka, M., & Szablewski, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125669 · Cited by 23
Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic
Seier, S., Stamp‐Larsen, K., Jensen, S. B. K., Torekov, S. S., & Gudbergsen, H. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70096 · Cited by 15
Wen, J., Nadora, D., Truong, A., Bernstein, E., How-Volkman, C., Razick, A. A., Razick, D., Karabala, M., & Frezza, E. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104213 · Cited by 20
Scragg, J., Koutoukidis, D. A., Dirksen, C., Heitmann, B. L., & Jebb, S. A. (2025) · Med · doi:10.1016/j.medj.2025.100805 · Cited by 16
Mesinovic, J., Hurst, C., Leung, G. K. W., Ryan, J. R., Daly, R. M., & Scott, D. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09968-3 · Cited by 26
“RCTs demonstrate significant weight loss of 16% (Semaglutide; 68 weeks) [129], 21% (Tirzepatide; 72 weeks) [130] and 24% (Retatrutide; 48 weeks) [131].”
Lyons, S. A., & Beaudry, J. L. (2023) · Endocrinology · doi:10.1210/endocr/bqad153 · Cited by 19
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 17
“Among the patient population in clinical trials, heterogeneity of responses is always observed, but the authors reported that up to 83% of patients (12 mg dose) achieved a 15% weight loss after 48 weeks [171], with tolerable reported GI side effects.”
Obesity – Standards, trends and advances
Gołacki, J., & Matyjaszek‐Matuszek, B. (2024) · Advances in Medical Sciences · doi:10.1016/j.advms.2024.04.001 · Cited by 17
Harnessing GLP‐1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon
Abdelrahman, R. M., Musa, T. H., Arbab, I. A., Suliman, M. H., Ahmed, E. O., Mohamed, A. N., Musa, H. H., Jalal, M., & Gasmallah, S. I. (2025) · Journal of Obesity · doi:10.1155/jobe/9919810 · Cited by 24
“We have highlighted this in the updated section on emerging therapies [38].”
Pasqualotto, E., Ferreira, R. O. M., Chavez, M. P., Hohl, A., Ronsoni, M. F., Pasqualotto, T., Moraes, F. C. A. D., Hespanhol, L., Figueiredo Watanabe, J. M., Lütkemeyer, C., et al. (2024) · Metabolism Open · doi:10.1016/j.metop.2024.100321 · Cited by 15
“Of these, three RCTs were included, comprising 640 patients [5,9,13].”
InfluentialIncretin and glucagon receptor polypharmacology in chronic kidney disease
McFarlin, B. E., Duffin, K. L., & Konkar, A. A. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00374.2023 · Cited by 17
Metadata
- Authors
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L.
- Affiliations
- Harvard University (US)
- From the Departments of Medicine (Endocrinology and Metabolism) and Pediatrics (Pediatric Endocrinology), Yale University School of Medicine, New Haven, CT (A.M.J.); the Obesity and Metabolism Institute and Department of Medicine, Harvard Medical School, Boston (L.M.K.); Velocity Clinical Research, Los Angeles (J.P.F.); and Eli Lilly, Indianapolis (Q.W., Y.D., S.G., T.C., A.H., Z.M., M.L.H.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-08-10
- Volume
- 389
- Issue
- 6
- Pages
- 514-526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4382049661
- Cited by
- 1,174
- References
- 28
- Citations by year
- 2026: 399 · 2025: 366 · 2024: 310 · 2023: 96
- FWCI
- 181.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- retatrutide, obesity, weight loss, dose-response relationship, adverse events, GLP-1 receptor agonists, GIP receptor agonist, glucagon receptor agonist, weight-related comorbidities, body mass index
- MeSH terms
- Adult, Double-Blind Method, Female, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Male, Obesity, Weight Loss, Body Mass Index, Treatment Outcome, Receptors, Glucagon, Anti-Obesity Agents, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.